The Drug Information Association (DIA) today announced that Dr. Jeff Goldsmith, Associate Professor, University of Virginia; President, Health Futures, Inc., will deliver the keynote address during a special session on comparative effectiveness research at the 46th DIA Annual Meeting.
The session titled, “Implications of Comparative Effectiveness Research for Health Care Innovation,” will convene a high-level panel that will present perspectives on what is required to develop and maintain a comparative effectiveness research/health technology assessment program with the end result of better and expedited care for the patient. Panelists will include:
- Mark B. McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, Brookings Institute
Michael D. Rawlins, Chairman, NICE; University of Newcastle
- Richard Gliklich, MD, President and CEO, Outcome Sciences Inc.
- Myrl Weinberg, President, National Health Council
- David B. Snow, Chairman of the Board and CEO, Medco Health Solutions, Inc.
Jack Lewin, MD, CEO, American College of Cardiology
“Comparative effectiveness research is an essential tool to manage the rapidly escalating costs of new treatment and technology,” says Paul Pomerantz, DIA Worldwide Executive Director. “This session will explore the global experience with comparative effectiveness research and health technology assessment (HTA) by examining the issues that the global medical community should consider as it strives for a patient-centered and consumer-driven health care marketplace.”
Dr. Goldsmith is one of the nation's foremost health industry analysts, specializing in corporate strategy, trend analysis, health policy and emerging technologies. He has worked across the health system—hospitals, health plans, physician groups, pharmaceutical, biotechnology and health manufacturing and distribution sectors.
The DIA Annual meeting attracts leading experts from industry, academia, patient organizations, and regulatory agencies from around the world who are involved in the discovery, development, and life cycle management of pharmaceuticals and related products. Additional highlights include:
350+ sessions across 25 content areas
- 1,100 speakers
- 8,000+ attendees from 80 countries
- 20 global regulatory agencies
- 550+ exhibiting companies
- Keynote address by US FDA Commissioner Dr. Margaret Hamburg
Register for the 46th DIA Annual Meeting
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.
Devine + Powers